ArticleArthritis research & therapy2019
Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era.
Article in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- PAFLAR guidelines for oligoarticular juvenile idiopathic arthritis.Clinical rheumatology · 2026Guideline
- Effect of exercise training on heath, quality of life, exercise capacity in juvenile idiopathic arthritis: a meta-analysis of randomized controlled trials.Pediatric rheumatology online journal · 2024Pooled it
- A randomized controlled educational study to evaluate an e-learning module to teach the physical examination of the temporomandibular joint in juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2024Trial
- Treatment of Juvenile Spondyloarthritis: Where We Stand.Paediatric drugs · 2020Trial
- African recommendations for diagnosis and management of systemic juvenile idiopathic arthritis (sJIA) - a PAFLAR initiative.Pediatric rheumatology online journal · 2026Article
- Comorbidities in Juvenile-Onset Rheumatic Diseases: A Systematic Review and Meta-Analysis.Children (Basel, Switzerland) · 2026Review
- Responsiveness of the EQ-5D-Y-5L Parent-Proxy Version Among Children with Juvenile Idiopathic Arthritis.The patient · 2026Article
- TAK1 inhibition restores p53 expression and suppresses inflammation and hyperplasia in JIA synovial fibroblasts.Rheumatology (Oxford, England) · 2026Article
- A stratified approach to juvenile idiopathic arthritis: leveraging machine learning to uncover subgroups of patients following treatment with etanercept.Rheumatology advances in practice · 2026Article
- Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice.Pediatric rheumatology online journal · 2025Article
- Juvenile arthritis damage index predicts poor response to biological treatment: A prospective cohort study.World journal of clinical pediatrics · 2025Article
- Real-life data on treatment strategies for polyarticular juvenile idiopathic arthritis.European journal of pediatrics · 2025Article
- Evaluating the causal effect of circulating proteome on the risk of Juvenile idiopathic arthritis: an omics pipeline study.Pediatric rheumatology online journal · 2025Article
- UBE2D1 as a key biomarker in systemic juvenile idiopathic arthritis: a new perspective on diagnosis and disease activity assessment.Arthritis research & therapy · 2025Article
- Cytokines in saliva, serum, and temporomandibular joint synovial fluid in children with juvenile idiopathic arthritis: An explorative cross-sectional study.Pediatric rheumatology online journal · 2025Article
- Assessment of the Damage Index and Its Dynamics in Patients with Non-Systemic Variants of Juvenile Arthritis during the Treatment with Biologics.Doklady. Biochemistry and biophysics · 2025Article
- Predictors of lack of response to methotrexate in juvenile idiopathic arthritis associated uveitis.Rheumatology (Oxford, England) · 2025Article
- Early Anti-Drug Antibodies Predict Adalimumab Response in Juvenile Idiopathic Arthritis.International journal of molecular sciences · 2025Article
- Frequency of remission achievement in the pre-treat-to-target decade in juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2025Article
- Inflammation-induced leg length discrepancy in children: from molecular mechanisms to clinical implications.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the long-term disease state, in terms of activity and damage, of children with juvenile idiopathic arthritis (JIA) who had their disease onset in methotrexate (MTX) or biologic eras.
methodsPatients were included in MTX or biologic era cohort depending on whether their disease presentation occurred before or after January 2000. All patients had disease duration ≥ 5 years and underwent a prospective cross-sectional assessment, which included measurement of disease activity and damage. Inactive disease (ID) and low disease activity (LDA) states were defined according to Wallace, JADAS10, and cJADAS10 criteria. Articular and extraarticular damage was assessed with the Juvenile Arthritis Damage Index (JADI).
resultsMTX and biologic era cohorts included 239 and 269 patients, respectively. Patients were divided in the "functional phenotypes" of oligoarthritis and polyarthritis. At cross-sectional visit, patients in the biologic era cohort with either oligoarthritis or polyarthritis had consistently higher frequencies of ID and LDA by all criteria. The measurement of disease damage at cross-sectional visit revealed that the frequency of impairment of > 1 JADI-Articular items was higher in MTX than in biologic era cohort (17.6% versus 11% in oligoarthritis and 52.6% versus 21.8% in polyarthritis). Likewise, frequency of involvement of > 1 JADI-Extraarticular items was higher in the MTX than in the biologic era cohort (26.5% versus 16.2% in oligoarthritis and 31.4% versus 13.5% in polyarthritis).
conclusionOur study provides evidence of the remarkable outcome improvement obtained with the recent therapeutic advance in JIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.